Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

Sign In to gain access to subscriptions and/or personal tools.
The British Journal of Diabetes & Vascular Disease
This Article
Right arrow Full Text (PDF)
Right arrow References
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by Barnett, A. H
Right arrow Search for Related Content
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Reviews

Review: Pharmacotherapy as part of a weight management programme: a UK perspective

Anthony H Barnett

University of Birmingham and Heart of England National Health Service Foundation Trust (Teaching), Birmingham, UK, anthony.barnett{at}heartofengland.nhs.uk

Rates of obesity and overweight continue to rise and substantially increase the risk of morbidity and mortality from type 2 diabetes, coronary and mortality from type 2 diabetes, coronary heart disease and stroke. On the other hand, a sustained weight loss of 5—10% in the obese confers marked health benefits. Current strategies for the management of obesity include lifestyle interventions and pharmacotherapy. At present, three drugs are approved for the medical management of obesity in the UK: orlistat, sibutramine and rimonabant. All three agents are efficacious in reducing body weight but by different mechanisms. Although weight loss is an important treatment outcome, a major goal of obesity management should be to improve cardiovascular and metabolic risk factors in order to reduce obesity-related morbidity and mortality. Given the similar levels of weight loss achievable with currently approved agents, treatment decisions should include careful assessment of the effects of these agents on cardiovascular and metabolic risk factors and on their long-term safety profiles. Br J Diabetes Vasc Dis 2007;7:268-77

Key Words: lifestyle interventions • obesity • orlistat • rimonabant • sibutramine • weight management.

The British Journal of Diabetes & Vascular Disease, Vol. 7, No. 6, 268-277 (2007)
DOI: 10.1177/14746514070070060301
Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?